Purple Biotech Shares Outstanding History (PPBT)
Purple Biotech reported 1.86B shares outstanding at the end of fiscal 2025.
View full Purple Biotech company overviewPurple Biotech annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 1.86B | 1.34B | +259.47% |
| 2024 | 2024-12-31 | 517.1M | 264.7M | +104.90% |
| 2023 | 2023-12-31 | 252.4M | 67.6M | +36.56% |
| 2022 | 2022-12-31 | 184.8M | 6.8M | +3.83% |
| 2021 | 2021-12-31 | 178.0M | 160.8M | +934.25% |
| 2020 | 2020-12-31 | 17.2M | −2.4M | −12.03% |
| 2019 | 2019-12-31 | 19.6M | 3.6M | +22.21% |
| 2018 | 2018-12-31 | 16.0M | — | — |
Purple Biotech quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 1.86B | 1.33B | +247.28% |
| Q1 2026 | 2026-03-31 | 1.86B | — | — |
| Q4 2025 | 2025-12-31 | 1.86B | 1.34B | +259.47% |
| Q3 2025 | 2025-09-30 | 1.81B | — | — |
| Q2 2025 | 2025-06-30 | 536.9M | — | — |
| Q4 2024 | 2024-12-31 | 517.1M | 264.7M | +104.90% |
| Q4 2023 | 2023-12-31 | 252.4M | 67.6M | +36.56% |
| Q4 2022 | 2022-12-31 | 184.8M | 6.8M | +3.83% |
| Q4 2021 | 2021-12-31 | 178.0M | 160.8M | +934.25% |
| Q4 2020 | 2020-12-31 | 17.2M | −2.4M | −12.03% |
| Q4 2019 | 2019-12-31 | 19.6M | 3.6M | +22.21% |
| Q4 2018 | 2018-12-31 | 16.0M | 0 | 0.00% |
| Q4 2017 | 2017-12-31 | 16.0M | — | — |
Purple Biotech shares outstanding trends
Over the last five fiscal years, Purple Biotech's shares outstanding moved from 17.2M to 1.86B, a change of 1.84B. The latest reported quarter, Q2 2026, shows 1.86B.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Purple Biotech source filings ↗